Mano T, Stevens RW, Ando K, Kawai M, Kawamura K, Nakao K, Okumura Y, Okumura T, Sakakibara M, Miyamoto K, Tamura T. Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate.
Chem Pharm Bull (Tokyo) 2005;
53:965-73. [PMID:
16079529 DOI:
10.1248/cpb.53.965]
[Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Structural modification of imidazole 5-lipoxygenase (5-LO) inhibitors for optimizing inhibitory potency, pharmacokinetic behavior and toxicity (ocular) profile led to 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]}phenyl-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide (6) with no observable ocular toxicity. The orally active and safe imidazole 5-LO inhibitor 6 was selected as a clinical candidate and advanced to clinical studies. An improved synthesis of 6 is also discussed.
Collapse